1. Die Widersprüche bzgl. eigene Exportlizenz bleibt virulent:
"Within our Stevioside segment, revenues from sales to third parties decreased by 24.0% and sales to the related party increased by 43.0% in fiscal 2016, as compared to fiscal 2015. We have been trying to develop our international market and increase the dependence of our sales torelated parties. Since we do not have the authorization to export products from China, we outsourced our exporting business to a related party, Qufu Shengwang Import and Export Corporation, which has authorizations to export"
...was ist denn nun mit der "100% Tochter" Shengren und deren Exportlizenz?
2. Einige Kennzahlen:
we produced 576 metric tons of stevioside for fiscal 2016 as compared to 366 metric tons in fiscal 2015 (erheblich gesteigert...leider mit halbierter Marge)
Gross margin on Stevioside segment for fiscal 2016 was 8.1%, as compared to 17.8% for fiscal 2015.
revenues stevioside 2016: 15,609,124 (ähnlich Vorjahr)
Loss before income taxes (stevioside): (3,338,883) (ähnlich Vorjahr)
Net loss 2016 - (4,796,866) 2015 - (4,522,139)
__________________________________________________
und hier ein besonders interessanter Posten:
Repayment of related party advances 2016 - (8,184,835) 2015 - (311,334)
"In fiscal years 2016 and 2015, we received advances from related parties for working capital totaled $8,559,771 and $905,738 respectively..."
schöner Nebenverdienst für Mr. Zhang..lest euch das Item 13 (bei Interesse) mal komplett durch
https://www.sec.gov/Archives/edgar/data/806592/000144878816000142/suwn10-k.htm
|